Prelude Capital Management’s Pfizer PFE Stock Holding History

Prelude Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,300	Closed	-$241K	–	1967
2021 Q2	$241K	Sell	7,300 -8,200	-53%	-$319K	0.01%	1309
2021 Q1	$562K	Sell	15,500 -42,500	-73%	-$1.51M	0.01%	842
2020 Q4	$2.13M	Buy	+58,000	New	+$2.13M	0.05%	281
2020 Q3	–	Sell	-2,951	Closed	-$92K	–	2222
2020 Q2	$92K	Sell	2,951 -843	-22%	-$28.6K	0.01%	981
2020 Q1	$118K	Sell	3,794 -48,063	-93%	-$1.64M	0.01%	556
2019 Q4	$1.93M	Sell	51,857 -41,106	-44%	-$1.46M	0.07%	229
2019 Q3	$3.17M	Buy	+92,963	New	+$3.38M	0.14%	99
2019 Q2	–	Sell	-26,350	Closed	-$1.06M	–	2039
2019 Q1	$1.06M	Buy	+26,350	New	+$1.06M	0.06%	317
2018 Q1	–	Sell	-71,672	Closed	-$2.46M	–	1669
2017 Q4	$2.46M	Buy	+71,672	New	+$2.44M	0.2%	102
2016 Q4	–	Sell	-40,052	Closed	-$1.29M	–	1729
2016 Q3	$1.29M	Buy	+40,052	New	+$1.34M	0.14%	172
2015 Q4	–	Sell	-1,054	Closed	-$31K	–	1632
2015 Q3	$31K	Buy	+1,054	New	+$33.8K	﹤0.01%	1165
2014 Q2	–	Sell	-22,239	Closed	-$678K	–	2108
2014 Q1	$678K	Buy	+22,239	New	+$663K	0.09%	302

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Prelude Capital Management's PFE Position: Q2 2026 in Review

Prelude Capital Management reduced its Pfizer (PFE) stake by 12% in Q2 2026, selling an estimated $432K and leaving 117,746 shares worth $2.84M. The position accounts for 0.21% of the portfolio, ranked #122.

Prelude Capital Management first reported a position in PFE in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.91M in Q4 2021. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Prelude Capital Management held 117,746 shares of Pfizer worth $2.84M as of Q2 2026.
Prelude Capital Management sold 16,506 Pfizer shares in Q2 2026, an estimated $432K.
Pfizer made up 0.21% of Prelude Capital Management's portfolio in Q2 2026, its #122 holding.
Prelude Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 39 quarters since.
Prelude Capital Management's Pfizer position peaked at $3.91M in Q4 2021.
2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.